PRMT5 and familial pancreatic carcinoma: However, our data with the CHLA-15 line, together with reports such as the sensitivity of c-MYC over-expressing pancreatic cancers to PRMT5 inhibition [62] suggest that threshold and context-dependent effects are important in c-MYC-driven cancers.